Authors:
de Sevaux, RGL
Gregoor, PJHS
Hene, RJ
Hoitsma, AJ
Vos, P
Weimar, W
van Gelder, T
Hilbrands, LB
Citation: Rgl. De Sevaux et al., A controlled trial comparing two doses of cyclosporine in conjunction withmycophenolate mofetil and corticosteroids, J AM S NEPH, 12(8), 2001, pp. 1750-1757
Authors:
Shaw, LM
Holt, DW
Oellerich, M
Meiser, B
van Gelder, T
Citation: Lm. Shaw et al., Current issues in therapeutic drug monitoring of mycophenolic acid: Reportof a roundtable discussion, THER DRUG M, 23(4), 2001, pp. 305-315
Authors:
van Gelder, T
Klupp, J
Barten, MJ
Christians, U
Morris, RE
Citation: T. Van Gelder et al., Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid, THER DRUG M, 23(2), 2001, pp. 119-128
Authors:
Barten, MJ
Gummert, JF
van Gelder, T
Shorthouse, R
Morris, RE
Citation: Mj. Barten et al., Assessment of mechanisms of action of immunosuppressive drugs using novel whole blood assays, TRANSPLAN P, 33(3), 2001, pp. 2119-2120
Authors:
Hesse, CJ
Vantrimpont, P
van Riemsdijk-van Overbeeke, IC
van Gelder, T
Balk, AHMM
Weimar, W
Citation: Cj. Hesse et al., The value of routine monitoring of mycophenolic acid plasma levels after clinical heart transplantation, TRANSPLAN P, 33(3), 2001, pp. 2163-2164
Authors:
Klupp, J
van Gelder, T
Dambrin, C
Regieli, J
Boeke, K
Billingham, ME
Morris, RE
Citation: J. Klupp et al., Mycophenolate mofetil pharmacodynamics and pharmacokinetics correlate withrejection score in a BN-to-LEW heterotopic heart transplant model, TRANSPLAN P, 33(3), 2001, pp. 2170-2171
Authors:
Klupp, J
Dambrin, C
Regieli, J
van Gelder, T
Shorthouse, R
Morris, RE
Citation: J. Klupp et al., New approach in drug development: Whole blood pharmacodynamic assays reflect biological activities of tacrolimus, TRANSPLAN P, 33(3), 2001, pp. 2172-2172
Authors:
van Besouw, NM
van der Mast, BJ
de Kuiper, P
Gregoor, PJHS
Vaessen, LMB
IJzermans, JNM
van Gelder, T
Weimar, W
Citation: Nm. Van Besouw et al., T-cell reactivity during azathioprine therapy compared with mycophenolate mofetil therapy, TRANSPLAN P, 33(3), 2001, pp. 2239-2240
Authors:
Barten, MJ
van Gelder, T
Gummert, JF
Shorthouse, R
Boeke, K
Billingham, ME
Morris, RE
Citation: Mj. Barten et al., New mechanisms of action of mycophenolate mofetil in transplant recipientsby assessment of its pharmacodynamics, TRANSPLAN P, 33(3), 2001, pp. 2254-2255
Authors:
van Gelder, T
Klupp, J
Sawamoto, T
Christians, U
Morris, RE
Citation: T. Van Gelder et al., ATP-binding cassette transporters and calcineurin inhibitors: Potential clinical implications, TRANSPLAN P, 33(3), 2001, pp. 2420-2421
Authors:
van der Mast, BJ
van Besouw, NM
de Kuiper, P
Vaessen, LMB
Gregoor, PJHS
IJzermans, JNM
van Gelder, T
Claas, FHJ
Weimar, W
Citation: Bj. Van Der Mast et al., Pretransplant donor-specific helper T cell reactivity as a tool for tailoring the individual need for immunosuppression., TRANSPLANT, 72(5), 2001, pp. 873-880
Authors:
Roodnat, JL
Mulder, PGH
Rischen-Vos, J
van Riemsdijk, IC
van Gelder, T
Zietse, R
Ijzermans, JNM
Weimar, W
Citation: Jl. Roodnat et al., Proteinuria after renal transplantation affects not only graft survival but also patient survival, TRANSPLANT, 72(3), 2001, pp. 438-444
Authors:
Vaessen, LMB
van Miert, PPMC
van Gelder, T
IJzermans, JNM
Weimar, W
Citation: Lmb. Vaessen et al., Reassuring effect of pravastatin on natural killer cell activity in stablerenal transplant patients, TRANSPLANT, 71(8), 2001, pp. 1175-1179
Authors:
Barten, MJ
Gummert, JF
van Gelder, T
Shorthouse, R
Morris, RE
Citation: Mj. Barten et al., Flow cytometric quantitation of calcium-dependent and -independent mitogen-stimulation of T cell functions in whole blood: inhibition by immunosuppressive drugs in vitro, J IMMUNOL M, 253(1-2), 2001, pp. 95-112
Authors:
van der Mast, BJ
van Besouw, NM
de Kuiper, P
Vaessen, LMB
IJzermans, JNM
van Gelder, T
Weimar, W
Citation: Bj. Van Der Mast et al., A longitudinal study of TGF-beta(1) protein levels in renal allograft recipients converted from CsA to MMF or AZA, CLIN TRANSP, 14(1), 2000, pp. 66-69
Citation: Pjhs. Gregoor et al., Mycophenolate mofetil, Cellcept (R), a new immunosuppressive drug with great potential in internal medicine, NETH J MED, 57(6), 2000, pp. 233-246
Authors:
Gummert, JF
Barten, MJ
van Gelder, T
Billingham, ME
Morris, RE
Citation: Jf. Gummert et al., Pharmacodynamics of mycophenolic acid in heart allograft recipients: Correlation of lymphocyte proliferation and activation with pharmacokinetics andgraft histology, TRANSPLANT, 70(7), 2000, pp. 1038-1049
Authors:
van Besouw, NM
van der Mast, BJ
de Kuiper, P
Gregoor, PJHS
Vaessen, LMB
Ijzermans, JNM
van Gelder, T
Weimar, W
Citation: Nm. Van Besouw et al., Donor-specific T-cell reactivity identifies kidney transplant patients in whom immunosuppressive therapy can be safely reduced, TRANSPLANT, 70(1), 2000, pp. 136-143
Authors:
Gregoor, PJHS
van Gelder, T
van Besouw, NM
van der Mast, BJ
Ijzermans, JNM
Weimar, W
Citation: Pjhs. Gregoor et al., Randomized study on the conversion of treatment with cyclosporine to azathioprine or mycophenolate mofetil followed by dose reduction, TRANSPLANT, 70(1), 2000, pp. 143-148
Citation: T. Van Gelder, Response: Randomized, concentration-controlled trial of MMF after kidney transplantation, TRANSPLANT, 69(8), 2000, pp. 1753-1754
Authors:
Baan, CC
van Gelder, T
Balk, AHMM
Knoop, CJ
Holweg, CTJ
Maat, LPWM
Weimar, W
Citation: Cc. Baan et al., Functional responses of T cells blocked by anti-CD25 antibody therapy during cardiac rejection, TRANSPLANT, 69(3), 2000, pp. 331-336